Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
American Journal of Therapeutics|August 1, 1994
Dose-Related Hepatic Blood Flow Effects Differentiate Nicorandil, Hydralazine, and Isosorbide Dinitrate in Healthy SubjectsDaniel L. Wolf, Carl M. Metzler, Monica O. Froeschke, et al.Journal of Clinical Pharmacology|February 1, 1993
Continuous intravenous dosing with ciprostene using a portable pump in ambulatory patientsD L Wolf, C M Metzler, M O Froeschke, et al.Clinical Pharmacology and Therapeutics|March 1, 1982
Converting enzyme inhibition with captopril in patients with primary hyperaldosteronismJ R Luderer, L M Demers, T S Harrison, et al.The Journal of Organic Chemistry|March 23, 2010
Effect of solvent and temperature on the lithium-bromine exchange of vinyl bromides: reactions of n-butyllithium and t-butyllithium with (E)-5-bromo-5-deceneWilliam F Bailey, Mark R Luderer, Daniel P Uccello, et al.Archives of Pathology & Laboratory Medicine|July 1, 1977
Immunologic myopathy. Linear IgG deposition and fulminant terminal episodeD M Judge, T J McGlynn, A B Abt, et al.The Journal of Physical Chemistry. A|July 13, 2006
Conformational effects on optical rotation. 2-Substituted butanesKenneth B Wiberg, Yi-gui Wang, Patrick H Vaccaro, et al.European Journal of Clinical Pharmacology|January 1, 1993
The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteersD L Wolf, J J Ferry, A E Hearron, et al.Research Communications in Chemical Pathology and Pharmacology|April 1, 1980
The effect of hydralazine on arachidonic acid metabolism in isolated, washed human plateletsJ R Luderer, L M Demers, R W Janson, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1988
Ciprostene in patients with peripheral vascular disease (PVD). An open-label, tolerance trialO I Linet, J R Luderer, M Froeschke, et al.Journal of Clinical Pharmacology|April 1, 1982
Captopril-induced skin eruptionsJ R Luderer, D P Lookingbill, D W Schneck, et al.Pageof 4